Accelerate Diagnostics, Inc. (AXDX)
- Previous Close
1.2200 - Open
1.2250 - Bid 1.2200 x 100
- Ask 1.3500 x 100
- Day's Range
1.1500 - 1.3100 - 52 Week Range
0.7300 - 11.9000 - Volume
56,800 - Avg. Volume
77,371 - Market Cap (intraday)
30.695M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9700 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.50
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
acceleratediagnostics.comRecent News: AXDX
Performance Overview: AXDX
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXDX
Valuation Measures
Market Cap
30.69M
Enterprise Value
55.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.58
Price/Book (mrq)
--
Enterprise Value/Revenue
4.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.60%
Return on Equity (ttm)
--
Revenue (ttm)
12.17M
Net Income Avi to Common (ttm)
-59.05M
Diluted EPS (ttm)
-3.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
15.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.66M